PURE Bioscience PURE today reported product revenues for the fiscal first quarter ended October 31, 2010 of $23,100, down from product revenues of $221,900 in the same quarter of the prior fiscal year.
The quarter's results include $355,000 in deferred revenue, recorded on the balance sheet as at October 31, 2010, which relates to a single international product shipment. The Company reported a net loss of $2,021,000 or $(0.06) per share for the fiscal first quarter, compared with a net loss of $1,711,200 or $(0.05) per share in the first fiscal quarter last year.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in